Cover Image

Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models

Colorectal cancer (CRC) is a major contributor to cancer-associated morbidity worldwide and over one-third of CRC is located in the rectum. Neoadjuvant chemoradiotherapy (nCRT) followed by surgical resection is commonly applied to treat locally advanced rectal cancer (LARC). In this review, we summa...

Full description

Saved in:
Bibliographic Details
Main Authors: Li, Moying (Author) , Xiao, Qiyun (Author) , Venkatachalam, Nachiyappan (Author) , Hofheinz, Ralf-Dieter (Author) , Veldwijk, Marlon Romano (Author) , Herskind, Carsten (Author) , Ebert, Matthias (Author) , Zhan, Tianzuo (Author)
Format: Article (Journal)
Language:English
Published: 2022
In: Therapeutic advances in medical oncology
Year: 2022, Volume: 14, Pages: 1-23
ISSN:1758-8359
DOI:10.1177/17588359221077972
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1177/17588359221077972
Get full text
Author Notes:Moying Li, Qiyun Xiao, Nachiyappan Venkatachalam, Ralf-Dieter Hofheinz, Marlon R. Veldwijk, Carsten Herskind, Matthias P. Ebert and Tianzuo Zhan
Description
Summary:Colorectal cancer (CRC) is a major contributor to cancer-associated morbidity worldwide and over one-third of CRC is located in the rectum. Neoadjuvant chemoradiotherapy (nCRT) followed by surgical resection is commonly applied to treat locally advanced rectal cancer (LARC). In this review, we summarize current and novel concepts of neoadjuvant therapy for LARC such as total neoadjuvant therapy and describe how these developments impact treatment response. Moreover, as response to nCRT is highly divergent in rectal cancers, we discuss the role of potential predictive biomarkers. We review recent advances in biomarker discovery, from a clinical as well as a histopathological and molecular perspective. Furthermore, the role of emerging predictive biomarkers derived from the tumor environment such as immune cell composition and gut microbiome is presented. Finally, we describe how different tumor models such as patient-derived cancer organoids are used to identify novel predictive biomarkers for chemoradiotherapy (CRT) in rectal cancer.
Item Description:Gesehen am 05.12.2023
Physical Description:Online Resource
ISSN:1758-8359
DOI:10.1177/17588359221077972

Similar Items